Drug intelligence / Profile preview

Auris-Sedina

Development stage: Phase 3
Lead developer: Laboratórios Osório De Moraes
Modality: Small Molecules
Administration: Otic

Overview

Auris-Sedina is a drug initially developed by Laboratórios Osório de Moraes Ltda. It has been investigated for the symptomatic control of otalgy (ear pain), particularly in patients with or without acute external otitis. The drug's highest reported development status is "Pending," and it has not yet received regulatory approval in any country. Its mechanism of action, molecular target, and modality are not specified in available sources. The primary therapeutic area appears to be ear, nose, and throat (ENT) conditions, specifically targeting pain associated with otitis[1][4][7].

Brand names: Auris-Sedina
Other names: cloranfenicol + dexametasona + lidocaína

Targets

GR (Glucocorticoid receptor)NaV (Voltage-gated sodium channels)Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on Auris-Sedina.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Auris-Sedina.

Explore the full profile